This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Amicus, Amarin, Oncothyreon

Stocks in this article: FOLD ONTY AMRN

Whalewisdom for tracking institutional and hedge fund stock ownership through 13F filings.

Subscription or paid services:

BioMedTracker: Hands down, the best, most complete database of historical clinical trial data and upcoming clinical and regulatory catalysts I've ever used. BioMedTracker is geared toward institutional investors but if you're a serious retail trader or investor, the price pays for itself.

I use CapitalIQ for company and sector financial and valuation data, access to sell-side research, conference call transcripts and full stock-screening capabilities. Another excellent research tool geared toward institutional investors but well worth it, especially if, like me, you're without access to a Bloomberg terminal.

StreetAccount: Real-time stock news, delivered via email. I'm a breaking-news junkie, of course, which makes StreetAccount the most valuable tool in my everyday work toolbox.

Biotech stock research services:

There's a small cottage industry of independent biotech research services out there. Many, thankfully, are priced reasonably enough for retail investors. Learning to do your own research is a great investing skill but the following subscription services, geared toward traders and more fundamentally oriented investors, are definitely worth considering.

Biotech Stock Research: David Miller and Alan Leong have been doing in-depth, fundamental research on small, development-stage biotechs for a long time. With most sell-side shops abandoning coverage of smallish biotech companies (or covering them only for banking reasons), Miller and Leong's independent research is even more valuable.

Chimera Research Group: Relative newbies but definite up-and-comers. Chimera does a good job of melding "geek" science research with options and active trading advice. These days, it's hard to make money in biotech investing without a bit of both.

SharkBiotech is run by a seasoned biotech trader, Dan Rosenblum, who acts and thinks more like a fundamental investor. It's a profitable mix of skill sets.

BioRunUp is for biotech traders, particularly those who like to trade biotech catalyst events such as FDA drug approvals and pending clinical trial results. Founder Mark Messier knows how to trade biotech stocks and he's built an online community of fellow active traders.

PelzOptions: Tony Pelz is a biotech options-trading guru and a member of the Chimera Research crew.

Full disclosure: Dan Rosenblum, Mark Messier and Tony Pelz are contributors to TheStreet.

Other helpful websites:

New England Journal of Medicine, Journal of Clinical Oncology, BioPharmCatalyst, Biotech Values Message Board , European Medicines Agency and Cafepharma.

Happy holidays and see you again in 2013.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs